This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up
by Zacks Equity Research
AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.
Quest Diagnostics Plans a Buyout to Widen TB Testing Suite
by Zacks Equity Research
Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.
STERIS (STE) Strategic Growth Strong Amid Several Headwinds
by Zacks Equity Research
STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.
Quest Diagnostics Inks Lab Service Deal With ReproSource
by Zacks Equity Research
Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.
Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp
by Zacks Equity Research
Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.
Cerner CommunityWorks Selected by Pershing Health System
by Zacks Equity Research
Cerner (CERN) witnesses consistent growth in the Electronic Health Record platform and Revenue Cycle Management solutions.
Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm
by Zacks Equity Research
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
Here's Why You Should Add Edwards Lifesciences Right Away
by Zacks Equity Research
We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.
Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod
by Zacks Equity Research
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
Will LabCorp's (LH) Food Solution Divestment Upset Sales?
by Zacks Equity Research
LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.
Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1
by Zacks Equity Research
Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.
Here's Why You Should Buy Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.
RTI Surgical's (RTIX) TETRAfuse Wins Spine Technology Award
by Zacks Equity Research
RTI Surgical (RTIX) to receive the Spine Technology Award from Orthopedics This Week at the NASS 33rd Annual Meeting in Los Angeles.
Boston Scientific Thrives in Urology on New LithoVue Empower
by Zacks Equity Research
Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.
Quest Diagnostics Grows in Fertility Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.
Abiomed's Impella Ensures Higher Survival Rates, Shares Up
by Zacks Equity Research
Abiomed's (ABMD) Impella successfully treats patients with cardiogenic shocks; market prospects bright.
Here's Why You Should Invest in Walgreens Boots Stock Now
by Zacks Equity Research
Walgreens Boots (WBA) gains from tie-ups. The company's alliance with Express Scripts encourages.
Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite
by Zacks Equity Research
Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.
Here's Why You Should Invest in PRA Health (PRAH) Stock Now
by Zacks Equity Research
The CRO industry's bullish prospects currently make PRA Health (PRAH) a promising investment pick.
Intuitive Surgical and InTouch Collaborate for IoMT Services
by Zacks Equity Research
Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.
TransEnterix's MST Medical Buyout to Boost Senhance Platform
by Zacks Equity Research
TransEnterix (TRXC) acquires Israel-based MST Medical, which will boost surgeons' effectiveness and make procedures quick and error-free.
Medical Instruments Stock Outlook: Long-Term Prospects Bright
by Zacks Equity Research
Research and development in the medical instruments industry is on the rise. FDA's approval of gene therapy for inherited renal disease and Big Data for healthcare set to revolutionize the field.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and a string of developments make Intuitive Surgical (ISRG) a promising pick.
Medtronic to Buy Mazor Robotics for Robotic Spine Surgery
by Zacks Equity Research
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.